The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Halozyme Therapeutics Inc (NASDAQ: HALO) closed at $73.97 in the last session, down -2.21% from day before closing price of $75.64. In other words, the price has decreased by -$2.21 from its previous closing price. On the day, 2.37 million shares were traded. HALO stock price reached its highest trading level at $75.57 during the session, while it also had its lowest trading level at $73.62.
Ratios:
We take a closer look at HALO’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 15.78 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.00. For the most recent quarter (mrq), Quick Ratio is recorded 7.01 and its Current Ratio is at 8.36. In the meantime, Its Debt-to-Equity ratio is 4.54 whereas as Long-Term Debt/Eq ratio is at 4.54.
Morgan Stanley Downgraded its Overweight to Equal-Weight on May 14, 2025, while the target price for the stock was maintained at $62.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 22 ’25 when LaBrosse Nicole sold 2,227 shares for $77.95 per share. The transaction valued at 173,584 led to the insider holds 22,079 shares of the business.
LaBrosse Nicole sold 20,000 shares of HALO for $1,514,267 on Sep 10 ’25. The SVP, CHIEF FINANCIAL OFFICER now owns 24,306 shares after completing the transaction at $75.71 per share. On Sep 10 ’25, another insider, NICOLE LABROSSE, who serves as the Officer of the company, bought 22,227 shares for $76.07 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HALO now has a Market Capitalization of 8847308800 and an Enterprise Value of 9641868288. As of this moment, Halozyme’s Price-to-Earnings (P/E) ratio for their current fiscal year is 16.90, and their Forward P/E ratio for the next fiscal year is 9.14. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.52. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.34 while its Price-to-Book (P/B) ratio in mrq is 26.15. Its current Enterprise Value per Revenue stands at 8.18 whereas that against EBITDA is 12.71.
Stock Price History:
The Beta on a monthly basis for HALO is 1.17, which has changed by 0.29840267 over the last 52 weeks, in comparison to a change of 0.15101504 over the same period for the S&P500. Over the past 52 weeks, HALO has reached a high of $79.50, while it has fallen to a 52-week low of $42.01. The 50-Day Moving Average of the stock is 8.25%, while the 200-Day Moving Average is calculated to be 24.75%.
Shares Statistics:
According to the various share statistics, HALO traded on average about 2.20M shares per day over the past 3-months and 2096480 shares per day over the past 10 days. A total of 117.62M shares are outstanding, with a floating share count of 115.68M. Insiders hold about 1.10% of the company’s shares, while institutions hold 100.37% stake in the company. Shares short for HALO as of 1756425600 were 11883269 with a Short Ratio of 5.36, compared to 1753920000 on 9932500. Therefore, it implies a Short% of Shares Outstanding of 11883269 and a Short% of Float of 14.180000000000001.
Earnings Estimates
Its stock is currently analyzed by 7.0 different market analysts. The consensus estimate for the next quarter is $1.85, with high estimates of $1.99 and low estimates of $1.65.
Analysts are recommending an EPS of between $6.31 and $5.38 for the fiscal current year, implying an average EPS of $6.05. EPS for the following year is $7.85, with 6.0 analysts recommending between $8.5 and $7.17.
Revenue Estimates
According to 7 analysts, the current quarter’s revenue is expected to be $339.18M. It ranges from a high estimate of $350M to a low estimate of $328.41M. As of the current estimate, Halozyme Therapeutics Inc’s year-ago sales were $290.08MFor the next quarter, 7 analysts are estimating revenue of $391.9M. There is a high estimate of $405.7M for the next quarter, whereas the lowest estimate is $378.4M.
A total of 9 analysts have provided revenue estimates for HALO’s current fiscal year. The highest revenue estimate was $1.34B, while the lowest revenue estimate was $1.31B, resulting in an average revenue estimate of $1.32B. In the same quarter a year ago, actual revenue was $1.02BBased on 8 analysts’ estimates, the company’s revenue will be $1.63B in the next fiscal year. The high estimate is $1.69B and the low estimate is $1.54B.
